【摘要】 白血病微小残留病(minimal residual disease, MRD)是指白血病患者经过诱导化疗或骨髓移植获得血液学完全缓解(hematologic complete remission, HCR)后，体内残存的形态学上不能检测到的少量白血病细胞。MRD可用于急性淋巴细胞白血病(acute lymphoblastic leukemia, ALL)的疗效评估，尤其是被用于复发预警、治疗方法的选择以及复发干预的指导。近年来，免疫干预和治疗逐渐成为恶性血液病治疗的热点。该文概述了ALL患者MRD的检测方法和意义，重点讨论并提出了MRD指导的ALL免疫干预和治疗策略。更多还原

【Abstract】 Leukemia minimal residual disease(MRD) refers to the small number of leukemia cells remaining in the body that is not morphologically detectable when patients achieve hematologic complete remission(HCR) after induction therapy or bone marrow transplantation. MRD is used in the evaluation of the therapeutic effect of acute lymphoblastic leukemia(ALL). It is especially used as an indicator for recurrence, selection of treatment methods, and guidance for recurrence intervention. In recent years, immune intervention and treatment have become the focus of hematological malignancy therapy. This review outlines the detection methods and significance of MRD in ALL patients and concentrates on discussing and proposing MRD-guided immune intervention and treatment strategies for ALL.更多还原